Company: APM
Filing Date: 2025-10-06
Form Type: S-4
Source: 0001213900-25-096656
Chunk: 433

Company: Aptorum Group Ltd
Filing Date: 2025-10-06
Form: S-4
Chunk 433
---
54,054 |
| Shares issued to DiamiR shareholders in merger                  |     | 19,917,413 |
| Warrants issuable for nominal consideration to Wainwright       |     |    247,525 |
| Weighted Average Shares Outstanding – Basic and Diluted         |     | 28,700,972 |

262 EXPERTS The consolidated balance sheets of Aptorum Group Limited as of December 31, 2024 and 2023, the related consolidated statements of operations and comprehensive loss, changes in equity and cash flows for each of the three years in the period ended December 31, 2024, and the related notes, included herein have been so incorporated in reliance on the report of Marcum Asia CPAs LLP, an independent registered public accounting firm, (which contains an explanatory paragraph relating to the Company’s ability to continue as a going concern as described in Note 2 to the financial statements) appearing in Aptorum’s annual report on Form 20 -Ffor the years then ended, included herein, given on the authority of such firm as experts in accounting and auditing. The consolidated balance sheet of DiamiR Biosciences Corp. as of May 31, 2025, and the related consolidated statements of operations, changes in stockholders’ deficit and cash flows for the year ended May 31, 2025, included in the Form S -4of Aptorum Group Limited, which is referred to and made a part of this proxy statement/prospectus, have been audited by CBIZ CPAs P.C., independent registered public accounting firm, as set forth in their report appearing elsewhere herein, which contains an explanatory paragraph relating to substantial doubt about the ability of DiamiR Biosciences Corp. to continue as a going concern as described in Note 2 to the financial statements, and are included in reliance upon such report given on the authority of such firm as experts in accounting and auditing. The consolidated balance sheet of DiamiR Biosciences Corp. as of May 31, 2024, and the related consolidated statements of operations, changes in stockholders’ deficit and cash flows for the year ended May 31, 2024, included in the Form S -4of Aptorum Group Limited, which is referred to and made a part of this proxy statement/prospectus, have been audited by Marcum LLP, independent registered public accounting firm, as set forth in their report appearing elsewhere herein, which contains an explanatory paragraph relating to substantial doubt about the